A multicenter real-world review of 10 kHz SCS outcomes for treatment of chronic trunk and/or limb pain.

High-frequency spinal cord stimulation (HF-SCS) at 10 kHz has proven to be efficacious in the treatment of chronic back and leg pain in a randomized, controlled, trial (SENZA-RCT). However, large observational studies have yet to be published. Therefore, we performed a real-world, multicenter, retrospective, review of therapy efficacy in 1660 patients with chronic trunk and/or limb pain. Data were collected in a real-world environment and retrospectively sourced from a global database. Included patients were trialed and/or permanently implanted with HF-SCS at 10 kHz between April 2014 and January 2018. We evaluated responder rates at 3, 6, and 12 months post-implantation. Response was defined as ≥50% pain relief from baseline. A last visit analysis included responder rate along with overall change in function, sleep, quality of life, and medication intake versus baseline. Eighty-four percent of our HF-SCS-treated patients had both chronic back and leg pain. At least 70% of patients reported response to therapy throughout 12 months of follow-up. This sustained responder rate was corroborated by the last visit value (74.1%). Most patients reported concomitant improvements in function (72.3%), sleep (68.0%), and quality of life (90.3%) at their last visit versus baseline. Thirty-two percent of patients reported decreased medication intake at their last visit. Sustained and effective pain relief was experienced by >70% of our HF-SCS-treated patients, consistent with the findings of a previously published randomized, controlled, trial. Our review provides complementary evidence to support the treatment of chronic back and leg pain with this therapy.

Déclaration de conflit d'intérêts

T. Stauss, G. Surges, D. Sayed, F. El Majdoub, W. S. Rosenberg, L. Kapural, R. Bundschu, A. Lalkhen, M. Maarouf and N. Patel are consultants to Nevro Corp., Redwood City, CA, USA. B. Gliner, J. Subbaroyan, and A. Rotte are employees of Nevro Corp., Redwood City, CA, USA. Funding was provided to Dr. Deborah Edgar in her capacity as a medical writer by Nevro Corp., Redwood City, CA, USA, for the preparation of this manuscript.